Utilization of Pharmacologic Treatment in Youths with Attention Deficit/Hyperactivity Disorder in Medicaid Database
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background: Little is known about longitudinal changes in drug utilization in attention-deficit/hyperactivity disorder (ADHD). Objective: To describe longitudinal trends in ADHD drug utilization and explore demographic differences among youths eligible for a large Southern state Medicaid program. Methods: A cross-sectional and longitudinal analysis of 10 years of claims data for all Medicaid beneficiaries younger than 20 years of age with 6 months or more of continuous insurance (N = 2,131,953) was conducted. Annual prevalence, incidence, and persistence in ADHD medication use (stimulants and atomoxetine) were estimated based on pharmacy claims and clinician-reported ADHD diagnosis. Results: ADHD prevalence increased 1.70-fold (95% CI 1.67 to 1.73) from 3.10% (21,904 of 705,573 beneficiaries) in fiscal year 1995–1996 to 5.27% (41,661 of 790,338) in 2003–2004, paralleled by a 1.84-fold (95% CI 1.81 to 1.87) increase in drug use to 4.63%. In 2003–2004, 0.69% of youths were diagnosed and newly started on drugs, reflecting a 1.38-fold (95% CI 1.33 to 1.43) increase over 1995–1996. One in five white males between the ages of 10 and 14 years (19.24%; 95% CI 18.81 to 19.67) received ADHD medication in 2003–2004. Males continued to be more likely diagnosed and treated than females (prevalence ratio [PR] in 2003–2004 = 2.96:95% CI 2.90 to 3.03 vs 3.82; 95% CI 3.69 to 3.96 in 1995–1996), as were whites when compared with Hispanics (PR in 2003–2004 = 2.65; 95% CI 2.57 to 2.73 vs 3.78; 95% CI 3.57 to 3.99 in 1995–1996) and blacks (PR in 2003–2004 = 1.81; 95% CI 1.76 to 1.85 vs 2.00; 95% CI 1.93 to 2.07 in 1995–1996). The most common starting age throughout the study period was 5–9 years, with 2.45% (95% CI 2.37 to 2.52) new ADHD drug users in 2003–2004, but largest increases in prevalence were observed in adolescents 15–19 years of age, with 2.47% (95% CI 2.38 to 2.55) in 2003–2004 compared with 0.45% (95% CI 0.41 to 0.49) in 1995–1996. Medication persistence varied, with only 49.9% (95% CI 49.4 to 50.5) of new users receiving drugs after 1 year, with yet another 17.2% (95% CI 16.4 to 18.0) continuing for 5 years or more. Conclusions: ADHD drug utilization continues to increase due to steady increases in diagnosis and chronic use of the drugs over several years. While racial, ethnic, and sex differences persist, the age distribution of drug users has shifted toward older children. These findings emphasize the need for studies that analyze determinants of treatment as well as outcomes, both benefits and risks, associated with long-term medication use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trends in the Prescribing of Psychotropic Medications to Preschoolers
Zito, J. M. (2000) · JAMA · doi:10.1001/jama.283.8.1025 · Cited by 863
Self-citationCooper, L. A., Gonzales, J. J., Gallo, J. J., Rost, K. M., Meredith, L. S., Rubenstein, L. V., Wang, N.-Y., & Ford, D. E. (2003) · Medical Care · doi:10.1097/01.mlr.0000053228.58042.e4 · Cited by 651
ADHD Drugs and Cardiovascular Risk
Nissen, S. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmp068049 · Cited by 331
Perwien, A. R., Hall, J., Swensen, A., & Swindle, R. (2004) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2004.10.2.122 · Cited by 136
Cited by
Polanczyk, G. V., Willcutt, E. G., Salum, G. A., Kieling, C., & Rohde, L. A. (2014) · International Journal of Epidemiology · doi:10.1093/ije/dyt261 · Cited by 1,822
Attention‐Deficit‐Hyperactivity Disorder: An Update
Dopheide, J. A., & Pliszka, S. R. (2009) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.6.656 · Cited by 645
Trends in Mental Health Care among Children and Adolescents
Olfson, M., Druss, B. G., & Marcus, S. C. (2015) · New England Journal of Medicine · doi:10.1056/nejmsa1413512 · Cited by 408
Storebø, O. J., Pedersen, N., Ramstad, E., Kielsholm, M. L., Nielsen, S. S., Krogh, H. B., Moreira-Maia, C. R., Magnusson, F. L., Holmskov, M., Gerner, T., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012069.pub2 · Cited by 321
Review of Medication Adherence in Children and Adults with ADHD
Adler, L. D., & Nierenberg, A. A. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.01.2112 · Cited by 295
Winterstein, A. G., Gerhard, T., Shuster, J., Johnson, M., Zito, J. M., & Saidi, A. (2007) · Pediatrics · doi:10.1542/peds.2007-0675 · Cited by 119
Self-citationSchulz, K. P., Fan, J., Bédard, A.-C. V., Clerkin, S. M., Ivanov, I., Tang, C. Y., Halperin, J. M., & Newcorn, J. H. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.2053 · Cited by 114
“A TTENTION-DEFICIT/HYPERactivity disorder (ADHD) is a highly prevalent and impairing psychiatric disorder that affects both children and adults and accounts for an outsized portion of psychotropic medication use in youth.(1) Yet, the mechanisms by which Food and Drug Administration–approved stimulant and nonstimulant…”
BackgroundImproving Medication Adherence in Chronic Pediatric Health Conditions: A Focus on ADHD in Youth
Chacko, A., H. Newcorn, J., Feirsen, N., & Z. Uderman, J. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791959908 · Cited by 66
Cardiac Safety of Methylphenidate Versus Amphetamine Salts in the Treatment of ADHD
Winterstein, A. G., Gerhard, T., Shuster, J., & Saidi, A. (2009) · Pediatrics · doi:10.1542/peds.2008-3138 · Cited by 56
Self-citationLisdexamfetamine Dimesylate: A New Therapeutic Option for Attention-Deficit Hyperactivity Disorder
Steer, C., Froelich, J., Soutullo, C. A., Johnson, M., & Shaw, M. (2012) · CNS Drugs · doi:10.2165/11634340-000000000-00000 · Cited by 30
“Dr Frölich Table III.”
BackgroundSelf-citation
Metadata
- Authors
- Winterstein, A. G., Gerhard, T., Shuster, J., Zito, J., Johnson, M., Liu, H., & Saidi, A.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2008-01
- Volume
- 42
- Issue
- 1
- Pages
- 24-31
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2155350946
- Cited by
- 132
- References
- 4
- FWCI
- 4.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.